Summary of Significant Accounting Policies - Additional Information (Details)		3 Months Ended		12 Months Ended
	Mar. 25, 2022 USD ($) Market	Mar. 31, 2025 USD ($) Market Segment ReportingUnits Institution	Mar. 31, 2024 USD ($)	Dec. 31, 2025	Dec. 31, 2024 USD ($)
Segment and Geographic Information
Number of operating segments | Segment		1
Number of reportable segment | Segment		1
Cash Equivalents
Cash Equivalents		$ 300,900,000
Concentration of Credit Risk
Number of financial institutions that hold the Company's cash | Institution		2
Business Combination
Number of reporting units | ReportingUnits		1
Goodwill		$ 12,042,000			$ 12,042,000
Accounts Receivable, net
Accounts receivable, Allowance for credit loss		$ 0
Equipment, net
Estimated useful life		3 years
License Agreements
Percentage of manufacturer discounts during the initial coverage phase		10.00%
Percentage of manufacturer discounts during the catastrophic coverage phase		20.00%
Cost of Product Sales
Payment terms		60 days or less
Advertising costs		$ 27,700,000	$ 24,000,000
Income Taxes
Effective tax rate		0.00%	0.00%
Income tax expense		$ 0	$ 0
Leases
Operating lease, lease term		12 months
Lessee, operating lease, existence of option to extend [true false]		false
Scenario Forecast
Income Taxes
Effective tax rate				0.00%
Sunosi
Cost of Product Sales
Number of Asian markets | Market		12
Revenue milestones	$ 165,000,000	$ 165,000,000
Development milestones	$ 1,000,000	$ 1,000,000
Sunosi | Jazz Pharmaceuticals Plc
Cost of Product Sales
Number of Asian markets | Market	12
Auvelity
Cost of Product Sales
License agreement royalty as a percent of net sales		3.00%